Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemotherapy vs Standard Treatment in IB2/IIA2 Cervical Cancer
NCT03308591Phase 3Completed
- Sponsor
- Huazhong University of Science and Technology
- Start
- Jan 2016
- Primary completion
- Feb 2022
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Cervical Cancer (CC) (2 arms), sponsored by Huazhong University of Science and Technology. Primary endpoint: Disease-Free Survival at 3 years. Started Jan 2016; status: completed.
02
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03308591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03308591.